Cargando…
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with check...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074764/ https://www.ncbi.nlm.nih.gov/pubmed/30105219 http://dx.doi.org/10.2147/OV.S145532 |
_version_ | 1783344482575450112 |
---|---|
author | Chen, Chun-Yu Hutzen, Brian Wedekind, Mary F Cripe, Timothy P |
author_facet | Chen, Chun-Yu Hutzen, Brian Wedekind, Mary F Cripe, Timothy P |
author_sort | Chen, Chun-Yu |
collection | PubMed |
description | Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy. |
format | Online Article Text |
id | pubmed-6074764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60747642018-08-13 Oncolytic virus and PD-1/PD-L1 blockade combination therapy Chen, Chun-Yu Hutzen, Brian Wedekind, Mary F Cripe, Timothy P Oncolytic Virother Review Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy. Dove Medical Press 2018-07-31 /pmc/articles/PMC6074764/ /pubmed/30105219 http://dx.doi.org/10.2147/OV.S145532 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Chen, Chun-Yu Hutzen, Brian Wedekind, Mary F Cripe, Timothy P Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title_full | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title_fullStr | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title_full_unstemmed | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title_short | Oncolytic virus and PD-1/PD-L1 blockade combination therapy |
title_sort | oncolytic virus and pd-1/pd-l1 blockade combination therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074764/ https://www.ncbi.nlm.nih.gov/pubmed/30105219 http://dx.doi.org/10.2147/OV.S145532 |
work_keys_str_mv | AT chenchunyu oncolyticvirusandpd1pdl1blockadecombinationtherapy AT hutzenbrian oncolyticvirusandpd1pdl1blockadecombinationtherapy AT wedekindmaryf oncolyticvirusandpd1pdl1blockadecombinationtherapy AT cripetimothyp oncolyticvirusandpd1pdl1blockadecombinationtherapy |